Completed PHASE4 INTERVENTIONAL 1-arm NCT00763438

Safety Study of an Antipsychotic, Sertindole, to Treat Schizophrenia

A Prospective, Open-label, Single-arm, Multinational, Multi-centre, Flexible-dose, Extension Study of the SCoP 99824 With Sertindole for Patients Suffering From Schizophrenia

Sponsor: H. Lundbeck A/S

Conditions Schizophrenia

Interventions Sertindole

Updated 5 times since 2017 Last updated: Nov 7, 2016 Started: Nov 30, 2007 Primary completion: Jul 31, 2010 Completion: Oct 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Schizophrenia, this trial is completed. The trial is conducted by H. Lundbeck A/S and has accumulated 5 data snapshots since 2007. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

H. Lundbeck A/S

Data source: H. Lundbeck A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Allonnes, France